Prof. Barbara Buldini

Curriculum Vitae

Scopus ID: 10639186000
Barbara Buldini is an internationally recognized expert of pediatric acute leukemias laboratory at diagnosis and in the response-to-therapy monitoring.
She is Associate Professor at the University of Padova, Italy (since 2021) and serves in the managerial position of Altissima Specialità -Referente di Branca Specialistica Leukemia Diagnosis (since 2020).
She is PI of Morphology and Flow Cytometry group at the Pediatric Onco-Hematology Laboratory in Padova, the AIEOP reference Laboratory for the diagnosis and MFC-MRD assessment of childhood acute leukemias (since 2018).
She is the scientific director of immunophenotype and MFC-MRD in ALL at first diagnosis and relapse, Infant ALL, and AML (AIEOP-BFM ALL trials) (since 2012).
She coordinates and collaborates on several national and international projects/groups/associations/societies.
She leads the Padua Lab as an AIEOP-BFM partner unit in the MFC training of ALLIC Labs with limited economic resources that use essentially MFC for monitoring MRD in ALL (Argentina and Georgia).
She coordinates the AIEOP-BFM-AML Flow MRD group with Prof. Dworzak (-since 2011).
She is Member of:
AIEOP-BFM Flow Network, including the principal national reference Laboratories of BFM and AIEOP for the standardization of immunophenotype at Diagnosis and MFC-MRD in childhood ALL (since 2006).
Trial Steering Committee of AIEOP-BFM ALL (since 2018) and AIEOP-BFM AML 2020 (since 2019) protocols.
ITCC (Innovative Therapies for Children with Cancer) Hema Committee, Villejiuf, France, (since 2021).
TDC_AIEOP-BFM_ALL_genetics team (since 2023).
She is Member for AIEOP of the Federal Tumor board (since2023).
She is PI of “Immunophenotypic Plasticity of Pediatric B Acute Lymphoblastic Leukemia: a Genomic Study” project founded by Cariparo foundation in the Pediatric Research Institute “Città della Speranza, Padua (since 2020).
She is an AIEOP Member in Ponte di Legno Group (since 2018).
She is national principal investigator of two Ponte di Legno Group studies: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and Gamma-Delta-positive T-ALL (since 2019).
She coordinates an ongoing study for Ponte di Legno group on ALL with Hypereosinophilia (since 2023).
She is member of: Gruppo di Lavoro (GdL) AIEOP “Biologia Cellulare e Molecolare” (since 2009); consultant of GdL AIEOP LAnL (Acute non-Lymphoblastic Leukemia – since 2012) and LLA (acute lymphoblastic leukemia – since 2018).
She is Tutor in “FlowInLab project” [https://elearning.unipd.it/flowinlab/], Moodle-based web-site developed in collaboration with DLM Office, University of Padua (since 2016).
She was Member of the iLTB (international leukemia/lymphoma target board) core team, coordinated by Princes Maxima Centrum (Utrecht), for Relapsed ALL (2021-2022).
She was Member of Board of Directors at AIEOP (2018-2021).
She participated to the ‘International Project Ambi Studio’ about Ambiguous Acute Leukemias, in collaboration with iBFM FLOW network (coordinated by Prof. O. Hrusak, Praga, Czech Republic), ALLIC and St. Jude’s Children Hospital, Memphis, Tennessee, USA.
She performed clinical track at Clinic of Pediatric Hematology-Oncology, IRCCS Policlinico San Matteo, University of Pavia, Italy, 2005-2006.
She is co-author for WHO 5th Edition, Precursor B cell Neoplasm.
Publications on peer reviewed Journals: 89 (Scopus h-index:29; Citations:2935)